South Shore Hospital Collaborates with Boston Children’s Hospital on New COVID-19 Research

In May 2021, South Shore Hospital, part of South Shore Health, partnered with Boston Children’s Hospital on a new COVID-19 clinical trial.

Patients admitted to the intensive care unit with severe COVID-19 pneumonia who require mechanical ventilation are invited to participate in this study.

The trial, designed by Dr. Benjamin Raby and his colleagues at Boston Children’s Hospital, is a randomized, double-blind, placebo-controlled trial where enrolled patients are randomized to receive either the study’s investigational medicine Pulmozyme (dornase alfa) with standard of care treatment or placebo with standard of care treatment.

Pulmozyme is currently U.S. Food and Drug Administration (FDA) approved in combination with standard therapies to improve lung function in pediatric and adult patients with cystic fibrosis, but is not FDA approved or authorized for treating COVID-19 pneumonia.

At South Shore Hospital, Dr. Dilip Nataraj, Chair of Critical Care, is leading the trial.

Genentech, a member of the Roche Group, is providing funding and  study drug for this research.

For more information, please visit